Celcuity Lands Its First FDA Approval With REVTORPYK

Celcuity crossed a defining threshold for any small-cap biotech: its first-ever FDA approval. The Minnesota-based company (NASDAQ: CELC) pairs a diagnostic platform with targeted oncology drugs, and its lead asset just became a commercial product.

On July 14, 2026, the FDA approved REVTORPYK (gedatolisib) for adults with HR-positive, HER2-negative, PIK3CA wild-type locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The drug is a first-in-class pan-PI3K/mTOR inhibitor and, according to the company, the only approved agent to block all class I PI3K isoforms alongside the mTOR complexes mTORC1 and mTORC2. Approval was based on the pivotal Phase 3 VIKTORIA-1 trial. Celcuity is targeting a commercial launch late in the third quarter of 2026 and plans to file a supplemental application in the same quarter for the larger PIK3CA-mutated population, which could widen the addressable market considerably.

Launching a first commercial product is capital-intensive and uptake against entrenched competitors is far from guaranteed. This is market commentary, not investment advice — small-cap biotech stocks are highly speculative and you can lose your entire investment.